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Background: P21-activated kinase 4 (PAK4), an effector of the Rho family protein Cdc42, is an important oncogene
whose expression is increased in many human cancers and is generally positively correlated with advanced disease
and decreased survival. However, little is known about the expression and biological function of PAK4 in human
non-small cell lung cancer (NSCLC).
Methods: PAK4 expression in NSCLC tissues and adjacent non-tumor tissues were assessed by immunohistochemistry,
real-time PCR, and western blotting. Prognostic value of PAK4 expression was evaluated by Kaplan-Meier analysis and
Cox regression. siRNA-mediated gene silencing and protein kinase assay was applied to demonstrate the role and the
mechanism of PAK4 in lung cancer cell migration, invasion.
Results: The results showed that PAK4 was overexpressed in NSCLC cell lines and human NSCLC tissues. PAK4
expression was detected both in the membranes and cytoplasm of NSCLC cancer cells in vivo. Moreover, increased
expression of PAK4 was associated with metastasis, shorter overall survival, advanced stage of NSCLC. Furthermore,
PAK4 expression was positively correlated with phosphorylation of LIMK1 expression levels. Knockdown of PAK4 in
NSCLC cell lines led to reduce the phosphorylation of LIMK1, which resulted in decrease of the cell migration and
invasion. In addition, PAK4 bound to LIMK1 directly and activated it via phosphorylation.
Conclusions: These data demonstrate that PAK4 mediated LIMK1 phosphorylation regulates the migration and
invasion in NSCLC. Therefore, PAK4 might be a significant prognostic marker and potential therapeutic molecular
target in NSCLC.
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Lung cancer is the leading cause of cancer-related death
around the world, and approximately 80–85 % of lung
cancers are non–small cell lung cancer (NSCLC) [1, 2],
which accounts for up to 85 % of such deaths [3, 4]. The
leading cause of death from NSCLC is metastasis, which
occurs even before the diagnosis of lung cancer is made,
leading to recurrence and treatment failure in patients* Correspondence: drweihb@126.com; lilian-75@163.com
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unless otherwise stated.[5–7]. Despite advances in therapeutic approaches, most
patients are diagnosed at the advanced stages, and the 5
year survival rate remains less than 15 % [8]. Therefore,
it is important to identify new predictive prognostic bio-
markers and to better understand the mechanisms of
disease progression.
P21-activated kinases (PAKs) are a family of serine/
threonine (Thr) protein kinases positioned at the nexus
of several oncogenic signaling pathways. Overexpression
or mutational activation of PAK isoforms frequently oc-
curs in various human tumors; given their involvement
in cancer cell motility, survival, apoptosis, and metasta-
sis, PAK isoforms are important regulators of cancer
cell signaling networks [9]. Based on their amino acids is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Fig. 1 PAK4 expression in NSCLC cell lines. a: Western blots of PAK4
expression in HBE cell line and A549, NCI-520, NCI-460, and NCI-H596
NSCLC cell lines (n = 3 replicate experiments; p < 0.05 vs. HBE cells).
b: Real-time PCR analysis of PAK4 expression in HBE, A549, NCI-520,
NCI-460, and NCI-H596 cells (n = 3 replicate experiments; p < 0.001 vs.
HBE cells)
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been identified and classified into group I (PAK1, 2, 3)
and group II (PAK4, 5, 6) PAKs [10, 11]. PAK4 was ini-
tially identified as an effector Cdc42, which is essential
for regulating cytoskeleton reorganization and filopodia
formation [12]. PAK4 is upregulated in many cancers
and is an important oncogene that promotes prolifera-
tion [13–16] and migration [15–23], and suppresses
apoptosis [24]. However, the role of PAK4 in NSCLC
remains unclear.
In this study, we discovered that PAK4 is overex-
pressed in NSCLC and that its overexpression is associ-
ated with poor prognosis. Knockdown of PAK4 inhibited
the migration and invasion of NSCLC cells. Further-
more, we found that PAK4 bound to LIM kinase 1
(LIMK1) directly and activated it via phosphorylation,
which is required for tumor cell motility and invasion.
These results suggest that PAK4 may play an import-
ant role in NSCLC cell migration and invasion, and
is a potentially useful prognostic marker and thera-
peutic target.
Materials and methods
Tissue specimens and cell lines
NSCLC tissue samples and adjacent normal tissue sam-
ples were acquired following the obtainment of informed
consent from the patients under institutional review
board-approved protocols. NSCLC primary tissue sam-
ples of ten patients without metastasis and ten patients
with metastasis and adjacent matched non-tumor tissues
were collected between October 2012 and January 2013
at the Third Affiliated Hospital, Sun Yat-sen University
(Guangzhou, China). The fresh tissue samples were im-
mediately snap-frozen in liquid nitrogen. 210 NSCLC
tissues were collected between January 2005 and January
2009. No patient had received treatment prior to enrol-
ment in this study. All diagnoses were histopatho-
logically confirmed. This study was approved by the
institutional research ethics committee of The Third
Affiliated Hospital, Sun Yat-sen University.
The following cell lines were used in this study: human
bronchial epithelial cells (HBE) and NSCLC cells (A549,
NCI-520, NCI-460, NCI-H596). All cell lines were ob-
tained from Cell Bank, Chinese Academy of Sciences
(Shanghai, China). The NSCLC cell lines were cultured
in RPMI 1640 (Gibco, Invitrogen Life Technologies,
Carlsbad, CA, USA) supplemented with 10 % newborn
calf serum (Gibco, Invitrogen Life Technologies).
HBE cells were maintained in keratinocyte serum-
free medium with 25 μg/ml bovine pituitary extract
and 0.2 ng/ml recombinant epidermal growth factor
(Invitrogen Life Technologies). Cells were transfected with
DNA constructs using siPORT™ NeoFX™ Transfection
Agent (Ambion) for 5 min.Immunohistochemistry
Immunohistochemical staining was performed using a
standard streptavidin-biotin-peroxidase complex method
(EnVision™ Detection System; Dako, Copenhagen,
Denmark). Tissue blocks were cut into 5-mm sections,
deparaffinized with xylene, and rehydrated in a graded
ethanol series. The sections were stained with anti-PAK4
(1:50; Cell Signaling Technology, Beverly, MA, USA)
overnight at 4 °C.
The degree of immunostaining was reviewed and
scored semiquantitatively by two independent observers.
The staining index was calculated as the product of the
proportion of positively stained tumor cells and the
staining intensity. The former was scored as follows: 0
(0 % positive tumor cells), 1 (<10 %), 2 (10–35 %), 3
(35–70 %), and 4 (>70 %). Staining intensity was graded
as follows: 0 (no staining), 1 (weak), 2 (moderate), and 3
(strong). The staining index was scored at 0–12. The
cutoff values for high and low PAK4 expression were
ascertained by measuring heterogeneity using log-rank
testing with respect to overall survival. A staining index
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index score of <6 indicated low PAK4 expression.
RNA isolation and quantitative real-time PCR
TRIzol reagent (Invitrogen Life Technologies) was used
to extract total RNA. Complementary DNA (cDNA) was
synthesized using a PrimeScript RT Reagent Kit
(Promega, Madison, WI, USA). Real-time PCR was per-
formed using Taqman universal PCR kit by an ABI
7900HT Fast Real-Time PCR system (Applied Biosystems,
Foster City, CA, USA). The following primers were
used: PAK4 forward 5′-ATGTGGTGGAGATGTA
CAACAGCTA-3′ and reverse 5′-GTTCATCCTGGTG
TGGGTGAC-3′; U6 forward 5′-TGCGGGTGCTCGFig. 2 Expression of PAK4 and the association with progression in NSCLC.
tissues (T) and matched adjacent non-tumor tissues (N); the quantitative in
adjacent non-tumor tissues. b: The mRNA expression of PAK4 in 20 NSCLC
expression in primary NSCLC cancer tissues of 10 patients without metastasis
staining (top panels) and statistical analysis (bottom panels) of squamous cell
matched adjacent non-tumor tissues (N) under at × 40 original magnification.CTTCGGCAGC-3′ and reverse 5′-CCAGTGCAGGG
TCCGAGGT-3′.
Western blotting and immunoprecipitation
Western blotting was performed as described previously
[25]. Proteins were separated using 10 % SDS-PAGE and
then transferred to nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA). The membranes were incubated
with rabbit anti-PAK4 (1:1000; Cell Signaling Technology),
anti-LIMK1 (1:1000; Cell Signaling Technology), anti–p-
LIMK1 (1:1000; Cell Signaling Technology), anti-cofilin
(1:1000; Cell Signaling Technology), and anti–p-cofilin
antibodies (1:1000; Cell Signaling Technology). The pro-
teins were visualized using ECL reagents (Pierce, Rockford,a Representative western blots of PAK4 expression (left) in NSCLC
tensities′ data of PAK4 protein bands of 20 NSCLC tissues and matched
tissues and matched adjacent non-tumor tissues by RT-PCR. c: PAK4
and 10 patients with metastasis. d: Representative immunohistochemical
cancer (left) and adenocarcinoma (right) of human NSCLC tissues (T) and
Positive cells are stained brown. P, patient
Table 1 Correlation of PAK4 expression with clinicopathological
variables in 210 cases of NSCLC
Variables PAK4 P Value*
All cases Low expression High expression
(n = 210) (n = 73) (n = 137)
Age (years)
≤60 103 35 68 0.816
>60 107 38 69
Gender
Male 136 48 88 0.826
Female 74 25 49
Histological type
SqCC 66 19 47 0.454
A 124 46 78
Other 20 8 12
Differentiation
Low 115 32 83 0.020
Moderate + high 95 41 54
T factor
T1 + T2 112 40 72 0.757
T3 + T4 98 33 65
Lymph node
N0 + N1 97 41 56 0.034
N2 + N3 113 32 81
Distant metastasis
M0 176 67 109 0.022
M1 34 6 28
Clinical stage
I + II 81 35 46 0.042
III + IV 129 38 91
*χ2 test; SqCC squamous cell cancer; A
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anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
antibody (Cell Signaling Technology). The intensity of pro-
tein fragments was quantified using GeneTools software
(version 3.03; Syngene, Cambridge, UK). Three independ-
ent experiments were performed for all western blotting
studies.
Immunoprecipitation assays were performed as de-
scribed previously [25]. A549 or NCI-H520 cells (6 × 106)
were solubilized in 400 μl cell lysis buffer (1 % Triton
X-100, 150 mM NaCl, 20 mM Tris-Cl [pH 7.4], 1 mM
EDTA, 1 mM EGTA, 1 mM Na3VO4, 2.5 mM pyro-
phosphate, 1 mM glycerol phosphate, and a protease
inhibitor mixture) for 10 min at 4 °C. The cell extract
was immunoprecipitated with 4 μg PAK4 (Cell Signaling
Technology) or LIMK1 (Cell Signaling Technology) anti-
body and then incubated with 60 μl Protein G Plus/Protein
A-Agarose (Santa Cruz Biotech). The precipitated immu-
nocomplexes were then boiled in Laemmli buffer and sub-
jected to western blotting with anti-LIMK1 or anti-PAK4
antibody.
Immunofluorescence
Cells were cultured on cover glasses, fixed using parafor-
maldehyde, and permeabilized with 0.1 % Triton X-100
in TBS. The cover glasses were incubated with the pri-
mary antibodies (anti-PAK4, Cell Signaling Technology;
anti-LIMK1, Cell Signaling Technology) at 1:50 dilu-
tions. PAK4 was detected with an anti-goat secondary
antibody conjugated to Alexa Fluor 488 (Invitrogen Life
Technologies). LIMK1 was detected with an anti-rabbit
secondary antibody conjugated to Alexa Fluor 555
(Invitrogen Life Technologies). The fluorescent staining
was visualized using a 63× NA 1.3 oil objective on a
confocal microscope (LSM 510 Meta; Carl Zeiss, Inc.).
The co-localization was analyzed using Pearson’s correl-
ation coefficient (full co-localization = 1.0) by the Image
Pro Plus software.
Protein kinase assay
PAK4 (WT) cDNA was cloned into a pET30a Escheri-
chia coli expression vector. The mutant vectors PAK4
(S445N) and PAK4 (K350M) were constructed by site-
directed mutagenesis. Recombinant activated PAK4
(S445N), kinase-defective PAK4 (K350M), and PAK4
(WT) proteins were purified from the E. coli expression
systems. LIMK1 protein was purchased from Invitrogen
Life Technologies. Equal amounts of the proteins were
incubated in buffer containing 100 mM NaCl, 10 mM
MgCl2, 50 mM HEPES (pH 7.5), 1 mM DTT, and 50 μM
ATP for 30 min at 30 °C. The protein kinase assay reac-
tion was terminated by the addition of 3× SDS sample
buffer. Western blotting was used to detect LIMK1
phosphorylation at Thr508.Matrigel invasion assays and transwell migration assays
For Matrigel invasion assays, 5 × 104 cells were added to
a matrigel invasion chamber (BD Biosciences, CA, USA).
FBS was added to the lower chamber as a chemoattract-
ant. After 24 h, the non-invading cells were removed
and invasive cells located on the lower side of the cham-
ber were stained with crystal violet. Transwell migration
assays were performed in a similar manner as the matri-
gel invasion assays but without matrigel on the filter.
Statistical analysis
Data from three independent experiments are presented
as the mean ± SE. All statistical analyses were performed
using SPSS software (version 17.0; IBM, New York, NY,
USA). Differences between variables were assessed
using the χ2 test. For survival analysis, all patients
with NSCLC were analyzed using Kaplan-Meier analysis.
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log-rank test. Using the Cox regression model, multivariate
survival analysis was performed on all parameters that
were significant in the univariate analysis. P-values < 0.05
were considered significant.
Results
Pattern of PAK4 expression in human NSCLC cell lines
or tissues
PAK4 overexpression has been reported in many human
cancers; however, its expression in NSCLC remains un-
clear. To explore PAK4 protein expression in NSCLC, weFig. 3 Kaplan-Meier survival curve illustrating the prognostic
significance of PAK4 expression in NSCLC. a: The patients (n = 210)
were divided into high or low PAK4 expression groups according to
the proportion of positively stained tumor cells and staining intensity.
5 year survival was calculated using the Kaplan-Meier method and
analyzed using the log-rank test. b: 5 year survival was calculated only
in the stage I + II cancer patients. c: 5 year survival was calculated only
in the stage III + IV cancer patientsexamined its expression in a human bronchial epithelial
cell line (HBE) and several NSCLC cell lines using western
blotting. All cancer cell lines expressed high levels of PAK4
protein compared with the HBE cell line (Fig. 1a). To de-
termine whether PAK4 was overexpressed at the transcrip-
tional level, we examined PAK4 mRNA levels in the HBE
and NSCLC cell lines using real-time PCR. The levels of
PAK4 mRNA in the NSCLC cell lines were significantly
higher than that in the HBE cell line (Fig. 1b), indicating
that PAK4 is overexpressed in NSCLC cell lines at both
mRNA and protein levels compared to HBE cells.
To investigate whether PAK4 was similarly upregu-
lated in NSCLC tissues, western blotting and real-time
PCR were performed on 20 NSCLC tissues (ten primary
tissues without metastasis and ten primary tissues with
metastasis) and matched adjacent non-tumor tissues.
PAK4 was overexpressed at both protein and mRNA
level in all 20 NSCLC tissues compared with the adja-
cent non-tumor tissues (Fig. 2a and b). Subgroup ana-
lysis showed that there was higher PAK4 mRNA in the
metastatic NSCLC tissues compared to the primary
NSCLC tissues (Fig. 2c).
Association between PAK4 expression and NSCLC
progression or prognosis
Based on the above results, we predicted that PAK4 over-
expression would be associated with disease progression.Table 2 Univariate and multivariate analysis of factors associated
with overall survival of patients with NSCLC
Clinical variable Case number HR (95 % CI) P Value
Uinvariate analysis
PAK4 (High vs. Low) 137/73 1.627(1.195–2.215) 0.002
Age (>60 vs. ≤60) 107/103 1.084(0.812–1.446) 0.584
Gender (Male vs. Female) 136/74 1.165(0.864–1.571) 0.317
Histological type (SqCC vs
A vs. Other)
66/124/20 1.069(0.832–1.374) 0.602
Distant metastasis (M1 vs. M0) 34/176 5.259(3.512–7.875) 0.000
T factor (T3 + T4 vs. T1 + T2) 98/112 1.090(0.817–1.455) 0.557
Lymph node (N2 + N3 vs.
N0 + N1)
113/97 5.349(3.852–7.426) 0.000









Distant metastasis (M1 vs. M0) 34/176 3.703(2.389–5.740) 0.000
Lymph node (N2 + N3 vs.
N0 + N1)
113/97 1.311(0.725–2.372) 0.371
Clinical stage (III + IV vs. I + II) 129/81 5.nn3.069–11.080) 0.000
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matched adjacent non-tumor tissues were stained using
immunohistochemistry. Positive staining was observed in
the NSCLC cell membranes and cytoplasm. The NSCLC
tissues had significantly higher PAK4 staining scores than
the adjacent non-tumor tissues (p < 0.01, Fig. 2d). There
was stronger PAK4 staining, indicating higher expression,
in 137 of 210 human NSCLC tissues (65.2 %). There were
no significant differences among the 3 subtypes of NSCLC:
adenocarcinoma, squamous cell carcinoma, and others
(p = 0.454, Table 1). Moreover, higher PAK4 staining
scores were positively correlated with differentiation,
lymph node metastasis, distant metastasis, and clinical
stage. These results reveal that PAK4 overexpression
was associated with NSCLC progression.
Kaplan-Meier analysis and log-rank testing showed
that overall survival was significantly different betweenFig. 4 PAK4 knockdown suppressed NSCLC cell migration and invasion. Th
cells transfected with siRNA(si-PAK4) or control siRNA(control) . Transwell migra
transfected with si-PAK4 or control under at × 40 original magnificationpatients with upregulated PAK4 and patients with down-
regulated PAK4 (p = 0.0016, Fig. 3a); patients with up-
regulated PAK4 had shorter overall survival. Subgroup
analysis also indicated that patients with high PAK4
expression had poor overall survival in both early stage
(I + II) and later stage (III + IV) patients (Fig. 3b, c).
Moreover, differentiation, lymph node invasion, distant
metastasis, and clinical stage correlated with survival.
When the clinicopathological variables that were signifi-
cant in univariate analysis were adopted as covariates,
multivariate Cox regression analysis indicated that
overexpression of PAK4 protein was an independent
prognostic factor for poor survival (p < 0.01, Table 2).
These results suggested that overexpression of PAK4
was positively associated with NSCLC progression
and might serve as an independent predictor of poor
survival.e protein (a) and mRNA (b) expression of PAK4 in A549 and NCI-H520
tion assay (c) and Matrigel invasion assay (d) of A549 and NCI-H520 cells
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These above data prompted us to further examine the
mechanism that PAK4 mediated in the progression of
NSCLC. First, PAK4 expression was downregulated by
siRNA-mediated gene silencing. Knockdown of en-
dogenous PAK4 in the A549 and NCI-H520 cells was
confirmed using western blotting and real-time PCR
(Fig. 4a and b). Then, Transwell migration assay and
Matrigel invasion assay were carried out to explore the
potential biological function of PAK4 in NSCLC. PAK4
knockdown suppressed A549 and NCI-H520 cell migra-
tion compared with the controls (Fig. 4c), and dramatic-
ally reduced A549 and NCI-H520 cell invasiveness
(Fig. 4d). Transfection with si-PAK4 decreased the num-
bers of migrated and invasive A549 and NCI-H520 cells
by >3-fold as compared with cells transfected the control
(both, p < 0.01). These results indicate that PAK4 knock-
down suppresses NSCLC cell migration and invasion.Fig. 5 LIMK1 was required for PAK4-mediated NSCLC cell migration and inv
in A549 and NCI-H520 cells transfected with si-PAK4 or control by western b
(red) in A549 cells (upper panels) or in NCI-H520 cells (lower panels). Nuclei
lysates were immunoprecipitated with PAK4 antibody (top panels) or LIM
ascertain LIMK1 and PAK4 interaction. d: In vitro kinase assay using purified
LIMK1 protein. The amount of p-LIMK1, PAK4, and LIMK1 were measured us
and the p-LIMK1 in human NSCLC tissues (n = 10). NC, negative control; IgGThe role of LIMK1 for PAK4-mediated NSCLC cell
migration and invasion
Cell migration requires reorganistion of the actin cyto-
skeleton. PAK4, an effector of Cdc42, elicits their
response via interaction with downstream effector pro-
teins. Previous studies showed that LIMK and its down-
stream cofillin activated by PAK4 plays an important
role in promoting actin polymerization and defining the
direction of cell motility [26]. We examined whether
LIMK1 and cofilin are involved in regulating NSCLC cell
line migration and invasion. Following siRNA knock-
down of PAK4, LIMK1, cofilin, and their respective
phosphorylation were examined using western blotting.
PAK4 knockdown significantly reduced the phosphor-
ylation of LIMK1 and cofilin, whereas the total ex-
pression levels of LIMK1 and cofilin did not change
(Fig. 5a). These results indicate that PAK4 might
regulate the the phosphorylation of LIMK1 and cofi-
lin in NSCLC cell.asion. a: The protein expression of LIMK1, p-LIMK1, cofilin, and p-cofilin
lotting. b: Immunofluorescent staining for PAK4 (green) and LIMK1
were stained with Hoechst33258 (blue). c: A549 and NCI-H520 cell
K1 antibody (bottom panels) and subjected to western blotting to
activated PAK4 (S445N), kinase-defective PAK4 (K350M), PAK4 (WT), and
ing western blotting. e: Correlations between the protein level of PAK4
, immunoglobulin G
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LIMK1 in vivo, we examined whether PAK4 physically
interacted with LIMK1 in the A549 and NCI-H520 cells
using by immunofluorescent staining. The results
showed that PAK4 (green) and LIMK1 (red) were pre-
dominantly localized within the cytoplasm (Fig. 5b). The
degree of co-localization was determined using Pearson’s
correlation coefficient; the mean ± SE of PAK4 and
LIMK1 colocalization was 0.72 ± 0.02 (n = 30) in the
A549 cells and 0.79 ± 0.03 (n = 30) in the NCI-H520
cells. These results showed that PAK4 and LIMK1 gen-
erally co-localized in the PC-3 and DU145 cells.
To investigate the role of PAK4 in the process of LIMK1
and cofilin phosphorylation, co-immunoprecipitation
assays were performed. Cell lysates were incubated with
PAK4 antibody, the immunocomplex was purified, sep-
arated by SDS-PAGE, and immunoblotted with a
LIMK1 antibody. The LIMK1 protein was present in
the complex immunoprecipitated with the anti-PAK4
antibody (Fig. 5c, top); PAK4 was also present in the
reciprocal immunoprecipitation with the anti-LIMK1
antibody (Fig. 5c, bottom). In addition, neither PAK4
nor LIMK1 were detected in the immunocomplex in
association with the control immunoglobulin G, indi-
cating the specificity of the observed co-association.
These results show that PAK4 interacts specifically with
LIMK1 in NSCLC cells.Fig. 6 LIMK1 overexpression rescued the effects of si-PAK4 on A549 and NCI-H
transfected with Si-PAK4 or LIMK1 or both, and then seeded for migrati
NC, negative controlPAK4 is an important oncogene in many cancers, and
many of its functions are dependent on PAK4 kinase ac-
tivity. To determine whether PAK4 directly phosphory-
lated LIMK1, we performed an in vitro kinase assay
using purified wild-type PAK4 (WT) and LIMK1 protein,
and found that LIMK1 was phosphorylated by PAK4
(Fig. 5d). We also used purified PAK4 with different ac-
tivities, activated PAK4 (S445N), kinase-defective PAK4
(K350M), and LIMK1 protein in the in vitro kinase
assay. LIMK1 phosphorylation in the presence of PAK4
(K350M) was significantly lower than that in the pres-
ence of PAK4 (WT) or PAK4 (S445N) (Fig. 5d). These
data indicate that PAK4 could phosphorylate LIMK1
protein.
To further reveal the relation between PAK4 and
phosphorylation of LIMK1 in clinical NSCLC tissues, we
examined the expression of PAK4 and p-LIMK1 in 20
human NSCLC tissues using western blotting. The ex-
tent of PAK4 upregulation was positively correlated with
the amount of p-LIMK1 (R2 = 0.657, p < 0.05) (Fig. 5e),
suggesting that the effect of PAK4 kinase activity on
LIMK1 is clinically relevant in human NSCLC tissues.
To reveal whether LIMK1 was involved in the PAK4-
mediated NSCLC cell migration and invasion, we co-
transfected A549 and NCI-H520 cells with si-PAK4 or
LIMK1 plasmid. LIMK1 rescued the effects of PAK4
knockdown on A549 and NCI-H520 cell migration and520 cell migration and invasion. A549 or NCI-H520 cells were transiently
on (a) and invasion assay (b) under at × 40 original magnification.
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LIMK1 phosphorylation is required for PAK4-mediated
NSCLC cell migration and invasion.
Discussion
Although PAK4 is an important oncogene in many can-
cers, the role of PAK4 in NSCLC remains obscure. In
this study, we detected PAK4 overexpression in NSCLC
cell lines and human NSCLC tissues, and found that
PAK4 overexpression was correlated significantly with
clinical stage, differentiation, lymph node metastasis,
and distant metastasis. More importantly, upregulated
expression of PAK4 in NSCLC patients was associated
with shorter overall survival. These results show that
PAK4 is an important prognostic marker and potential
therapeutic target in NSCLC.
Upregulated PAK4 promotes cell migration in several
cancers [13–23]. However, the role of PAK4 in NSCLC
cell migration remains unclear. As far as we know, this
is the first study to reveal that PAK4 increase NSCLC
cell migration and invasion. Furthermore, PAK4 regula-
tion of cell migration is dependent on the downstream
pathway of membrane-type 1 matrix metalloproteinase
(MT1-MMP) in choriocarcinoma [15, 16], c-Src/mitogen-
activated protein kinase kinase 1 (MEK1)/extracellular
signal-regulated kinase (ERK)1/2 and MMP-2 in ovar-
ian cancer [16], LIMK1/cofilin in prostate cancer [17],
MMP-2 in glioma [19], and superior cervical ganglia 10
(SCG10) or LIMK1/cofilin in gastric cancer [20, 21].
We revealed that PAK4 promoted migration by directly
binding to LIMK1 and activating it via phosphorylation.
It has been reported that the PAK4-LIMK1-cofilin sig-
naling pathway promotes cell migration in prostate can-
cer and gastric cancer [17, 20]. Other signal pathways
through which PAK4 mediates NSCLC migration re-
quire further exploration.
LIMK1, a downstream effector of PAK4, is an import-
ant regulator of cytoskeletal organization involved in cell
migration [27, 28]. LIMK1 is overexpressed in lung can-
cer and is associated with high tumor-nodes-metastasis
(TNM) stage and lymph node metastasis [29]. Our ex-
periments also showed that LIMK1 was overexpressed
in NSCLC tissues, especially in tissues with metastasis
(data not shown). Furthermore, si-LIMK1 suppressed
the migration and invasion of lung cancer cells [29].
However, how modulating LIMK1 promotes lung cancer
cell migration remains unclear. In this study, we found
that LIMK1 interacted directly with PAK4 and acted as a
substrate to promote cell migration and invasion in
NSCLC. Furthermore, overexpression of LIMK1 rescued
the effects of PAK4 knockdown on NSCLC cell migra-
tion and invasion. These findings show that PAK4
increased NSCLC cell migration by phosphorylating
LIMK1.CDK5 kinase regulatory subunit-associated protein 3
(CDK5RAP3) in hepatocellular cancer [22] and hepato-
cyte growth factor (HGF) and follicle-stimulating hor-
mone (FSH) in ovarian cancer [16] activate PAK4 to
promote cell migration. HGF and c-Met are overex-
pressed in NSCLC [30]. However, the upstream path-
ways of PAK4 in NSCLC cell migration remain unclear.
We intend to explore the mechanism of PAK4 activation
in NSCLC in future studies.
Conclusion
In the present study, increased PAK4 expression was
associated with differentiation, lymph node metastasis,
distant metastasis, clinical stage, and an unfavorable
prognosis in patients with NSCLC. Our findings suggest
that thePAK4-LIMK1 pathway may be related to the
progression of NSCLC and that PAK4 may be significant
prognostic marker for this disease.
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